Radiofrequency renal denervation with different device for treatment in patient with uncontrolled hypertension

Objective. To study the efficacy and safety of radiofrequency renal denervation with mono-electrode and multi-electrode devices in patients with uncontrolled arterial hypertension during follow-up period. Materials and methods. The study included 42 patients with uncontrolled arterial hypertension (mean age 51±12 years), while receiving multicomponent antihypertensive therapy, including diuretic. All patients underwent radiofrequency denervation of the renal arteries with a mono-electrode (n=27; group A) and multi-electrode devices (n=15; group B). The safety of the procedure was assessed using creatinine and glomerular filtration rate (MDRD equation), as well as according to ultrasound of the kidneys and renal arteries. The effectiveness of the procedure was study according to office blood pressure (BP) and ambulatory BP monitoring (ABPM). Results. In the general group, according to office BP after 6 months, there decreased in systolic (SBP)/diastolic BP (DBP) by 28/13 mm Hg (p=0.000001). According to ABPM, there was a decrease in the average daily SBP by 9 mm Hg (p=0.007) and DBP by 6 mm Hg (p=0.03). No significant changes in creatinine and glomerular filtration rate were detected in the general group. According to ABPM, after 6 months in group B, there was a decrease in the average daily SBP/DBP by 13 and 6 mm Hg (p=0.1). In group A, according to the ABPM, after 6 months, there was a decrease in the average daily SBP and DBP by 7 mm Hg (p=0.001) and 4 mm Hg (p=0.03). After 1 year, according to the office BP, there was a decrease in SBP/DBP by 14/11 mm Hg (p=0.002), and after 3 years at 15/17 mm Hg (p=0.3). Conclusion. The results confirm the safety and efficacy of radiofrequency renal denervation. Renal denervation in combination with drug therapy leads to decreasing of BP after 6 months and in the long-term

arterial hypertension, renal denervation, mono-еlectrode catheter, multi-electrode catheter

1. Siddiqui M, Dudenbostel T, Calhoun D.A. Resistant and refractory hypertension: antihypertensive treatment. Canada J Cardiol 2015; 32 (5): 603-6.

2. Sakakura K, Ladich E, Cheng Q. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol 2014; 64 (7): 635-43. https://doi: 10.1016/j.jacc.2014.03.059

3. Григин В.А., Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Радиочастотная денервация почечных артерий. Миф или реальность? Системные гипертензии. 2015; 12 (3): 39-45.

4. Данилов Н.М., Елфимова Е.М., Савченко А.П., Чазова И.Е. Реноваскулярная артериальная гипертензия, диагностика и лечение. Кардиологич. вестн. 2010; 10 (3): 32-41.

5. Krum H, Schlaich M.P, Sobotka P.A et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383 (9917): 622-9. https://doi:10.1016/S0140-6736(13)62192-3

6. Symplicity HTN-2 Investigators, Esler M.D, Krum H, Sobotka P.A et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9. https://doi: 10.1016/S0140-6736(10)62039-9

7. Esler M.D, Böhm M, Sievert H et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35 (26): 1752-9. https://doi:10.1093/eurheartj/ehu209

8. Pocock S.J, Bakris G, Bhatt D.L et al. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. J Am Coll Cardiol 2016; 68 (18): 2016-25. https://doi:10.1016/j.jacc.2016.07.775

9. Sievert H, Schofer J, Ormiston J et al. Bipolar radiofrequency renal denervation with the Vessix catheter in patients with resistant hypertension: 2-year results from the REDUCE-HTN trial. J Hum Hypertens 2017; 31 (5): 366-8. https://doi:10.1038/jhh.2016.82

10. Kandzari D, Böhm M, Mahfoud F et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; p. 1-10. http://dx.doi.org/10.1016/S0140-6736(18)30951-6

11. Данилов Н.М., Матчин Ю.Г., Чазова И.Е. Эндоваскулярная радиочастотная денервация почечных артерий - инновационный метод лечения рефрактерной артериальной гипертонии. Первый опыт в России. Ангиология и сосудистая хирургия. 2012; 18 (1): 51-4.

12. Агаева Р.А., Данилов Н.М., Щелкова Г.В. и др. Клинический случай. Применение метода радиочастотной денервации почечных артерий мультиэлектродным биполярным устройством при рефрактерной артериальной гипертонии. Кардиологич. вестн. 2017; 13 (2): 76-9.

13. Fengler K, Ewen S, Hollriegel R et al. Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. J Am Heart Assoc 2017; p. 1-7. https://doi:10.1161/JAHA.117.006196